Nature Technology Corporation is now part of Aldevron. NTC Technologies product information is moving on December 30, 2022.

Learn More

Enabling Endless Possibilities

Enabling Endless Possibilities

The Nature Technology Story

As a leading developer and provider of non-viral vectors, technologies and services for advancing gene and cell therapy and immunotherapy, our mission is to improve the effectiveness, safety, availability and economy of gene based medicines, and our goal is to aid in the discovery and dissemination of improvements for the benefit of our industry partners and ultimately the patients we all serve.

We provide a development pipeline, platform, and process – from conception to delivery – for a wide variety of preventive and therapeutic gene based medicines.

Our technologies are applicable to a broad range of therapeutic products, including: DNA vaccination, allergy immunotherapy, passive immunotherapy, reverse vaccination, stem cell therapies, adoptive immunotherapy, personalized medicines, viral vector production, orphan drugs, regenerative medicines, cancer therapy, gene replacement therapies, diabetes mellitus, autoimmune disorders gene silencing therapeutics, and more.

Since our founding in 1998 by a small group of researchers led by former CEO and founder, Dr. Clague Hodgson and inventor and CSO, Dr. Jim Williams, and Aaron Carnes, VP of Manufacturing, Nature Technology has been at the forefront of genetic non-viral vector technology. And now, with the addition of Deborah Moorad as CEO, that same commitment toward maximizing the promise and potential of nucleic acid-based drugs grows even stronger.

Revolutionizing non-viral vector technology, one breakthrough after another.

Today, Nature Technology is redefining what’s possible in genetic engineering, cell therapy and immunotherapy.

Executive Team

2020 Publications

Suschak JJ, Dupuy LC, Shoemaker CJ, Six C, Kwilas SA, Spik KW, Williams JA, Schmaljohn CS, Molecular Therapy Methods and Clinical Development 2020 April

2018 Publications

Karlsson I, Borggren M, Rosenstierne MW, Trebbien R, Williams JA, Vidal E, Vergara-Alert J, Foz DS, Darji A, Sisteré-Oró M, Segalés J, Nielsen J, Fomsgaard A. Vet Immunol Immunopathol. 2018 Jan;195:25-32.

2017 Publications

Suschak JJ, Williams JA, Schmaljohn CS. Hum Vaccin Immunother. 2017 Dec 2;13(12):2837-2848.

Lu J, Williams JA, Luke J, Zhang F, Chu K, Kay MA. Hum Gene Ther. 2017 Jan;28(1):125-134.

2016 Publications

Borggren M, Nielsen J, Karlsson I, Dalgaard TS, Trebbien R, Williams JA, Fomsgaard A. Vaccine. 2016 Jul 12;34(32):3634-40.

2015 Publications

Borggren M, Nielsen J, Bragstad K, Karlsson I, Krog JS, Williams JA, Fomsgaard A. Hum Vaccin Immunother. 2015;11(8):1983-90.

2014 Publications

Foster LK, Kromm MM, McComb B, Williams JA, Luke J, Carnes A, Hodgson CP, Foster DN, (2014), Avian Diseases 58: 566-571.

Williams, J.A. (2014) Current Gene Ther. 14:170-189.

Carnes AE, Williams JA, Process for DNA Immunization Applications, in: Monica Rinaldi et al. (eds.), DNA Vaccines: Methods and Protocols, Methods in Molecular Biology, vol. 1143, p197-217, Springer Science+Business Media, New York.

Luke JM, Carnes AE, Williams JA, Development of Antibiotic-Free Selection System for Safer DNA Vaccination, in: Monica Rinaldi et al. (eds.), DNA Vaccines: Methods and Protocols, Methods in Molecular Biology, vol. 1143, p 91-111, Springer Science+Business Media New York.

Dou C1, Lay F2, Ansari AM2, Rees DJ2, Ahmed AK2, Kovbasnjuk O3, Matsangos AE2, Du J2, Hosseini SM2, Steenbergen C4, Fox-Talbot K4, Tabor AT5, Williams JA6, Liu L2, Marti GP2, Harmon JW2., Mol Ther. 2014 Apr;22(4):752-61. doi: 10.1038/mt.2014.2. Epub 2014 Jan 17.

2013 Publications

Jared Nelson, Stephen Rodriguez, Neil Finlayson, Jim Williams and Aaron Carnes, (2013), Human Vaccines & Immunotherapeutics (2013), 9:10, 2211–2215.

2011 Publications

Carnes, A.E., Luke, J.M., Vincent, J.M., Schukar, A., Anderson, S., Hodgson, C.P., Williams, J.A. Biotechnol. Bioeng. (2011). Feb;108(2):354-63.

Luke, J.M., Carnes, A.E., Hodgson, C.P., Williams, J.A. Mol. Biotechnol. (2011). 47(1):43-9.

Luke, J.M., Simon, G.G., Soderholm, J., Errett, J.S., August, J.T., Gale, J., Hodgson, C.P., Williams, J.A. (2011). J. Virol. 85:1370-83.

Luke, J., Carnes, A.E., Sun, P., Hodgson, C.P., Waugh, D.S., and Williams, J.A., (2011). J. Biotechnol., 151:242-50.

Luke, J., Vincent, J.M., Du, S.X., Whalen, B., Leen, A., Hodgson, C.P., and Williams, J.A.. Gene Ther.18:334-343 (2011)

2010 Publications

Carnes, A.E., Luke, J.M., Vincent, J.M., Anderson, S., Schukar, A, Hodgson, C.P., and Williams, J.A. J. Gene Medicine, (12(10):818-31).

2009 Publications

Carnes, AE, Hodgson, CP, Luke, JM, Vincent, JM, Williams, JA, Biotechnol. Bioeng. 104:505-515 (2009)

Luke J, Carnes AE, Hodgson CP, Williams JA. Vaccine 27(46):6454-9.(2009)

James A Williams *, Jeremy Luke, Sarah Langtry, Sheryl Anderson, Clague P Hodgson, Aaron E Carnes, Nature Technology Corporation, Lincoln, NE, USA. Biotechnol. Bioeng. (2009) 103:1129-1143

Carnes AE, Williams JA, Gen Eng. Biotech News, (2009) 29:56-57

Williams, J.A., Carnes, A.E., and Hodgson, C.P. (2009). Biotechnology Advances. (2009) 27:35-370

Williams, J.A., Hodgson, C.P., and Carnes, A.E. (2009).BioPharm International 22(11):46-51

2007 Publications

Carnes, A., Williams, J., (2007) Current Patents on Biotechnol. 1(2):151-166.C

2006 Publications

James A Williams, Jeremy Luke, Lance Johnson, Clague Hodgson, (2006) Vaccine 24:4671-4676